Strides Pharma Science Share News - Latest Updates, Live News & More

Latest news about Strides Pharma Science

Strides Pharma Science Expands U.S. Nasal Spray Portfolio Through Kenox Partnership Sep 08, 2025

Strides Pharma Science has formed a strategic partnership with Kenox Pharmaceuticals Inc. to develop multiple nasal spray products for the U.S. market. The collaboration aims to leverage Kenox's expertise in Orally Inhaled and Nasal Drug Products (OINDPs) and Strides' manufacturing and market presence. This move is expected to accelerate Strides' nasal spray offerings and strengthen its position in the U.S. pharmaceutical market. The partnership focuses on developing affordable, high-quality therapies across various therapeutic indications.

Strides Pharma Science Streamlines Operations: Deregisters Non-Operating South African Subsidiary Aug 25, 2025

Strides Pharma Reports Strong Q1 Results with 19.5% EBITDA Margin and 81% EPS Growth Aug 04, 2025

Strides Pharma Projects Quarterly Operating Costs of ₹460-470 Crore, Aims for Debt Elimination in 3-4 Years Jul 30, 2025

Strides Pharma Reaffirms U.S. Revenue Target of $300-400 Million by 2028 Jul 30, 2025

More news about Strides Pharma Science

29Jul 25

Strides Pharma Reports 7% US Sales Growth and Margin Expansion in June Quarter

Strides Pharma Science announced financial results showing a 6.2% year-over-year revenue increase to ₹1,119.70 crore. Gross margin expanded by 300 basis points to 60.3%. EBITDA grew 10% to ₹78.00 crore, with margin improving to 7%. US business revenue grew 7% to $70 million. The company recorded an exceptional loss of ₹8.40 crore and a one-time gain of ₹3,188.00 crore. Management expressed satisfaction with the results, citing cost management and execution. Shares traded 3.2% higher at ₹952.00 following the announcement.

22May 25

Strides Pharma Science Reports Strong Q4 Results with US Business Outperforming

Strides Pharma Science announced impressive Q4 results, with US business revenue reaching $291 million, a 21.80% year-over-year increase. Q4 EBITDA rose 6.37% to 2.17 billion rupees. Overall revenue grew 7.89% to 1160.20 crore Rs, while net profit surged 66.36% to 90.00 crore Rs. The company's EPS increased by 76.06% to 9.56 Rs. Despite strong performance, Strides cautioned about potential inconsistencies in growth markets over the next two years.

22May 25

Strides Pharma Science Ltd: Q4 Profit Soars, Outperforms Guidance

Strides Pharma Science announced strong Q4 results with revenue rising 14% to ₹1,190.00 crore and net profit soaring 722.1% to ₹85.60 crore. The US business grew by 23.2% to $77.00 million, while EBITDA increased 6.5% to ₹217.00 crore. Full-year revenue growth exceeded guidance at 17.2%. The company declared a dividend of ₹4.00 per share.

30Apr 25

Strides Pharma Bolsters Anti-Inflammatory Portfolio with FDA Approval for Celecoxib Capsules

Strides Pharma Science Limited has received USFDA approval for Celecoxib Capsules in 100 mg, 200 mg, and 400 mg strengths. The product, bioequivalent to Celebrex® Capsules, targets a US market worth $116 million. Manufactured in Puducherry, India, this approval enhances Strides' anti-inflammatory offerings. The company also recently acquired four ANDAs from Nostrum Laboratories for $2.08 million, further diversifying its US product portfolio.

29Apr 25

Strides Pharma Expands US Portfolio with $2.075 Million ANDA Acquisition

Strides Pharma Science's US subsidiary has acquired four approved ANDAs from Nostrum Laboratories for $2.08 million. The portfolio targets UTIs, pain management, allergy symptoms, and ADD/ADHD treatments, with a cumulative market size of $57 million. Two of the four ANDAs are expected to launch within 12 months, expanding Strides' portfolio of niche and difficult-to-manufacture products in the US market.

07Apr 25

Strides Pharma Recalls 4.4 Lakh Cartons of Testosterone Gel in US Market

Strides Pharma has initiated a recall of over 440,000 cartons of Testosterone Gel in the United States due to the detection of a foreign substance in the product. This recall demonstrates the company's commitment to patient safety and quality control. The incident may have short-term implications for Strides Pharma's revenue and market presence in the testosterone replacement therapy segment. The company has not yet released information about the financial impact or timeline for resolving the issue.

04Apr 25

Strides Pharma Recalls Over 440,000 Cartons of Testosterone Gel in US Market

Strides Pharma, Inc. has initiated a Class II recall of more than 440,000 cartons of Testosterone Gel in the United States due to benzene contamination. The recall affects two products: 195,952 cartons of 1% Testosterone Gel, 2.5 grams, and 244,412 cartons of 1% Testosterone Gel, 5 grams. The recall was initiated on March 5th in response to the detection of benzene, a known carcinogen not intended to be in the product. This situation may have implications for Strides Pharma's market position in the US and could lead to increased scrutiny of their manufacturing processes.

19Mar 25

Strides Pharma Science Unveils Strategic De-Merger Plan for Arco Lab's Life Sciences and Digital Innovation Business

Strides Pharma Science Limited's Board has approved the de-merger of its subsidiary Arco Lab's Life Sciences and Digital Innovation Capabilities into a new company (NewCo). The NewCo will be a wholly-owned subsidiary of Strides, focusing on Life Sciences and Manufacturing solutions. This restructuring aims to create a specialized entity without financial impact on Strides. Arco Lab will proceed with incorporating NewCo, drafting the scheme of arrangement, and conducting business valuation.

17Mar 25

Strides Pharma Science Subsidiary Eyes Southeast Asian Expansion with Amexel Acquisition

A subsidiary of Strides Pharma Science Ltd plans to acquire a 100% stake in Amexel Pte. Ltd., a Singapore-based company. This strategic move aims to strengthen Strides' presence in Southeast Asia and create a robust business platform in the region. The acquisition aligns with the growing pharmaceutical market in Southeast Asia, driven by increasing healthcare expenditure, population growth, and rising chronic diseases. While financial details remain undisclosed, this acquisition marks a significant step in Strides' international growth strategy.

14Mar 25

Strides Pharma Science Expands Footprint in Southeast Asia with Strategic Acquisition

Strides Pharma Science's subsidiary, Strides Pharma Global Pte. Limited, plans to acquire Amexel Pte. Ltd. for USD 10, aiming to strengthen its Southeast Asian presence. The acquisition, set to complete by March 31, 2025, focuses on technology transfer, supply chain enhancement, and market expansion. Amexel will operate on a revenue generation and profit-sharing model, facilitating partnerships and commercialization across the region.